Huiyu Pharmaceutical announced that in 2025, the company plans to sign a national general agency agreement for “TY-9591” products with Tongyuankang. The agreement was signed by the subsidiary Huichenxin and Tongyuankang on February 9, 2026. The milestone amount of 150 million yuan is to be paid after the payment conditions are met. On July 22, 2026, the company received a subpoena and Tong Yuankang sued to confirm that the relevant agreement had not been established; previously, the company and its subsidiaries had sued to confirm that the agreement was legal and valid. Both cases have been filed and are yet to be heard, and the impact on profits cannot be anticipated due to unpaid and unknown results.

Huiyu Pharmaceutical announced that in 2025, the company plans to sign a national general agency agreement for “TY-9591” products with Tongyuankang. The agreement was signed by the subsidiary Huichenxin and Tongyuankang on February 9, 2026. The milestone amount of 150 million yuan is to be paid after the payment conditions are met. On July 22, 2026, the company received a subpoena and Tong Yuankang sued to confirm that the relevant agreement had not been established; previously, the company and its subsidiaries had sued to confirm that the agreement was legal and valid. Both cases have been filed and are yet to be heard, and the impact on profits cannot be anticipated due to unpaid and unknown results.